Bayer stock kpis
Want to see BAYRY full AI Analyst Report?
Revenue by Segment
In Q2 2026, Bayer reported revenue by segment of €59.00M (Other), €4.91B (Crop Science), €4.46B (Pharmaceutical) and €1.45B (Consumer Health).
Shows how different business units contribute to overall sales, highlighting strengths, diversification, and areas of growth or concern within the company’s operations.
Bayer's Crop Science segment shows a cyclical pattern with peaks in Q1, but a gradual decline in peak values since 2022 suggests potential market saturation or competitive pressures. The Pharmaceutical segment remains stable, indicating resilience despite broader economic challenges. Consumer Health exhibits modest growth, hinting at increased demand for health products. Without new earnings call insights, the focus should be on Crop Science's strategic adjustments to regain momentum and capitalize on Consumer Health's steady growth.
BAYRY Revenue by Segment
| Period | Other | Crop Science | Pharmaceutical | Consumer Health |
|---|---|---|---|---|
| Q2 2026Jun 30, 2026 | €59.00M | €4.91B | €4.46B | €1.45B |
| Q1 2026Mar 31, 2026 | €107.00M | €7.56B | €4.25B | €1.49B |
| Q4 2025Dec 31, 2025 | €105.00M | €5.40B | €4.48B | €1.46B |
| Q3 2025Sep 30, 2025 | €52.00M | €3.86B | €4.33B | €1.42B |
| Q2 2025Jun 30, 2025 | €54.00M | €4.79B | €4.47B | €1.43B |
| Q1 2025Mar 31, 2025 | €111.00M | €7.58B | €4.55B | €1.50B |
| Q4 2024Dec 31, 2024 | €119.00M | €5.38B | €4.66B | €1.57B |
| Q3 2024Sep 30, 2024 | €59.00M | €3.99B | €4.51B | €1.41B |
| Q2 2024Jun 30, 2024 | €100.00M | €4.98B | €4.61B | €1.46B |
| Q1 2024Mar 31, 2024 | €68.00M | €7.91B | €4.36B | €1.43B |
| Q4 2023Dec 31, 2023 | €75.00M | €5.63B | €4.58B | €1.58B |
| Q3 2023Sep 30, 2023 | €29.00M | €4.37B | €4.54B | €1.41B |
| Q2 2023Jun 30, 2023 | €97.00M | €4.92B | €4.56B | €1.47B |
| Q1 2023Mar 31, 2023 | €58.00M | €8.35B | €4.41B | €1.57B |
| Q4 2022Dec 31, 2022 | €52.00M | €5.57B | €4.86B | €1.52B |
| Q3 2022Sep 30, 2022 | €86.00M | €4.69B | €4.96B | €1.55B |
| Q2 2022Jun 30, 2022 | €44.00M | €6.46B | €4.82B | €1.50B |
| Q1 2022Mar 31, 2022 | €56.00M | €8.45B | €4.62B | €1.51B |
| Q4 2021Dec 31, 2021 | €72.00M | €4.69B | €4.95B | €1.41B |
| Q3 2021Sep 30, 2021 | €46.00M | €3.85B | €4.54B | €1.35B |
| Q2 2021Jun 30, 2021 | €49.00M | €5.02B | €4.49B | €1.29B |
| Q1 2021Mar 31, 2021 | €65.00M | €6.65B | €4.37B | €1.25B |
| Q4 2020Dec 31, 2020 | €93.00M | €4.18B | €4.48B | €1.25B |
| Q3 2020Sep 30, 2020 | €44.00M | €3.03B | €4.23B | €1.21B |
| Q2 2020Jun 30, 2020 | €59.00M | €4.80B | €3.99B | €1.20B |
| Q1 2020Mar 31, 2020 | €67.00M | €6.83B | €4.55B | €1.40B |
| Q4 2019Dec 31, 2019 | €79.00M | €4.65B | €4.68B | €1.34B |
| Q3 2019Sep 30, 2019 | €90.00M | €3.95B | €4.50B | €1.29B |
| Q2 2019Jun 30, 2019 | €61.00M | €4.79B | €4.42B | €1.44B |
| Q1 2019Mar 31, 2019 | €59.00M | €6.44B | €4.35B | €1.40B |

